HE CD 1 1 b SUBUNIT, a member of the leukocyte integrin family, is present on the surface of human neutrophils as one of the two subunits of the CD1 1b/CD18 adhesion receptor.'.' The leukocyte integrins are composed of one of three different CD1 I subunits (CDlla, CDllb, or CD 1 IC) noncovalently associated with a common CD1 8 subunit. 3 The individual CD1 1 subunits are expressed in different lineage-specific patterns on leukocytes. CD1 l b expression is highest in terminally differentiated myeloid cells, including granulocytes, monocytes, and macrophage^.^,^ CD 1 1 b is also expressed on a small subset of CD5+ B cells: a small subset of CD8+ T cell^,^^^ and a very small subset of CD4+ T cells.' CD1 1b is not expressed in nonhematopoietic cells or hematopoietic cells of erythroid or megakaryocytic lineage.6 Expression of CD1 l b is thus highly regulated and occurs predominantly in myeloid cells.
The molecular mechanisms that direct CD1 l b expression may provide insight into myeloid gene expression. For instance, there may exist master regulatory molecules directing the expression of myeloid genes or the expression of leukocyte integrins. Identification of these regulatory factors could provide unifying principles for understanding how lineage specificity is controlled during hematopoietic differentiation. This identification might increase understanding of the pathogenesis of human myeloid leukemias, in which the differentiation program has been arrested." Furthermore, identification of myeloid-specific regulatory sequences and factors could provide a tool to target the expression of biologically active proteins to the myeloid cells of transgenic animals.
The CD 1 I b promoter has been cloned and analyzed extensively in cell lines.""' Sequence analysis of the CD1 Ib promoter indicates that, unlike other tissue-specific genes, it does not contain a CAAT or TATA box. In transient transfections, the CD1 l b promoter is active in myeloid cells, and sequences located within 72 or 242 bp of the transcription start site have been reported to confer myeloid-specific expression.".l4 However, it is not known whether the proximal CD1 1 b promoter contains the sequences required for complete tissue-specific regulation of the CD1 1b gene in vivo. To address this question, we introduced three different CD1 1b promoter fusion genes into the germline of the mouse. The fusion transgene in all cases consists of the CD1 Ib promoter driving a human CD4 reporter gene and a human growth hormone (hGH) minigene. Because CD1 l b normally requires association with CD18 before surface expression of the CD1 1 b/CD18 heterodimer, human CD4 was chosen as a reporter gene because it can be expressed as a single-cell surface molecule. The three different transgene constructs use either 1.5, 0.3, or 0.1 kb of the CD1 Ib promoter sequence.
The results of these studies indicate that the 1 S-kb CD1 1b promoter is capable of directing the expression of the reporter gene in leukocytes of transgenic mice. However, the pattern of transgene expression does not consistently resemble expression of the endogenous CD1 Ib gene. In addition, the reporter gene expression in these CD1 Ib promoter transgenic mice appears to be dependent on integration site and is unrelated to transgene copy number. These findings suggest that sequences in addition to the proximal CD1 lb promoter will likely be required for lineage-specific expression of reporter genes in myeloid cells.
MATERIALS AND METHODS
Plasmid construction and generation of transgenic mice. The 1 5 , 0.3-, and 0.1-kb CD1 l b promoter fragments were generated using the polymerase chain reaction (PCR) to amplify the CD1 1 b promoter fragment from a human genomic CD1 Ib clone identified previously." This procedure was designed to add a Hind111 site to the 5' end of the CD1 Ib promoter and a BamHI site to the 3' end. The human CD4 cDNA was removed as a BamHI fragment from the plasmid pMCV7. The CD1 Ib promoter fragments were ligated to a mutated human CD4 cDNA and cloned into the p0GH plasmid.'6 The human CD4 cDNA is mutated at bp 1348 (C -+ T) to produce a premature termination codon, resulting in truncation of the cytoplasmic domain of the transgenic human CD4, and was a gift of Roger Perlmutter (University of Washington, Seattle, WA). Plasmids containing the transgenic constructs were prepared using cesium chloride equilibrium centrifugation. The CD1 Ib-hCD4-hGH fusion genes were excised from plasmid using Hind111 and Nsi I (Fig I) . The transgenic construct DNA was isolated on 0.8% agarose gels and recovered using SpinX (Costar, Cambridge, MA) columns. The resulting DNA was further purified using Qiagen-5 tips (Qiagen, Chatsworth, CA) and resuspended in TE at 100 ng/pL. The microinjections were performed by DNX, Inc (Princeton, NJ).
Transgenic founder mice were identified by slot blot analysis of genomic DNA prepared from l-cm tail clips. All procedures involving mice were approved by the University of Washington Animal Care Committee. The slot blots were probed with a BamHI 1.7-kb human CD4 fragment made from the transgene construct. After hybridization, the blots were washed at 65°C and exposed overnight.
Founder animals were bred with C57BL mice (Jackson Labs, Bar Harbor, ME) to establish transgenic lines that were heterozygotic for the transgenic fusion gene. A PCR assay was used to identify transgenic F1 animals. Primers were synthesized (Applied Biosysterns, Foster City, CA) such that the PCR product would span the human CD4-human growth hormone portion of the transgene (Fig  I) . The 5' primer sequence is based on human CD4 (bp 1517-1541): CGG-ACC-AGA-TGA-ATG-TAG-CAG-ATC-C. The 3' primer sequence is based on human growth hormone (bp 829-859): AAA-CCC-TGA-GCT-CCT-TAG-TCT-CCT-CCT-CTT. A typical 50 pL PCR reaction used 30 ng of tail DNA, 1 pL Vent polymerase (New England Biolabs, Boston, MA), 1OX Vent polymerase buffer supplied by the manufacturer, and 0.2 mmol/L dNTPs. The PCR parameters were 95°C for 10 minutes followed by 95°C for 1 minute, 55°C for 1 minute, 72°C for 1 minute for 30 cycles. Ambiguous PCR results were resolved by performing DNA slot blots. All analyses were performed using F1 heterozygotic transgenic animals, except for flow cytometry studies of peripheral blood from sterile founder animals.
Assessment of transgene integrity and copy number. Transgene integrity was tested by using genomic DNA in Southern blots. For the 1.5-kb CD1 l b promoter-hCD4-hGH construct, the DNA was cut with Bgl I1 to produce a 4.4-kb restriction fragment that included the entire hCD4 cDNA. For 0.3-kb and 0.1-kb CDllb promoter constructs, the DNA was cut with BamHI to produce a 1.7-kb restriction fragment (Fig 1) . Blots were performed using Zetaprobe membranes (BioRad, Richmond, CA), hybridized, and washed in sodium phosphate buffer as described by the manufacturer at 65°C. A scanning densitometer (Molecular Dynamics, Sunnyvale, CA) was used to estimate relative copy numbers for each founder line.
Detection of transgene expression in tissue. Transgene expression was assessed using RNA slot blots and Northern blots. RNA was extracted from mouse organs (including spleen, marrow, lymph node, kidney, lung, thymus, muscle, liver, and brain) using a singlestep method with Ultraspec (Tel-test, Friendswood, TX). RNA slot blots were made using nitrocellulose membranes (S&S, Keene, NH) following established procedures.'7 The blots were washed at 65°C in 0.1 X SSC, 0.1% sodium dodecyl sulfate (SDS).
Flow cytometry to assess hCD4 reporter gene expression on leukocytes. Peripheral blood was obtained by retroorbital puncture of anesthesized mice. The red blood cells were lysed using Trisammonium chloride, washed once, and resuspended in phosphatebuffered saline (PBS). Splenocytes were prepared by teasing cells out of the spleen capsule and washing the cells once in PBS. Peritoneal macrophages were obtained by lavaging the peritoneal cavity with 5 mL of PBS. Human lymphocytes were used as a positive control for human CD4. Murine splenocytes were used as a positive control for CD45R/B220. Murine granulocytes from murine peripheral blood were used as a positive control for antimurine CD1 lb. Cells were treated with blocking rat IgG for at least 15 minutes before adding specific monoclonal antibodies. Staining was performed at 4°C for at least 30 minutes with saturating concentrations of either antimurine CD1 lb-fluorescein isothiocyanate (FITC; Serotec, Oxford, UK), antimurine B220-FITC (Pharmingen, San Diego, CA), or anti-Gr-l-FITC (Pharmingen)," and antihuman CM-phycoerythrin (PE) (Becton Dickinson, Mountain View, CA). After staining, the cells were washed twice in PBS and 5% fetal calf serum, and resuspended in PBS and 5% fetal calf serum and 7-amino-actinomycin D (7AAD) at 5 pg/mL. The cells were analyzed within 3 hours on a FACScan (Becton Dickinson) using Lysis I1 acquisition software. Nonviable cells staining positively with 7AAD were identified using FL3 versus forward scatter histograms and excluded from analysis. Data on 50,000 viable cells were collected for each sample. For studies using peripheral blood leukocytes, lymphocytes and granulocytes were identified on histograms displaying forward scatter versus side scatter. Monocytes usually did not appear as a distinct population in these preparations. For studies of peritoneal cells, macrophages were identified on histograms displaying foward scatter versus side scatter. All histograms are 3-decade log/ log scales. Lymphocytes, granulocytes, and macrophage populations were confirmed by Wright's staining of sorted cells. Further analysis of list mode data files was performed using ReproMan (True Facts, Seattle, WA).
RESULTS
Generation of transgenic mice carrying CD1 l b promoterhCD4-hGH jksion genes. The three CDllb promoterhCD4-hGH transgenic constructs used to generate transgenic mice are shown (Fig l) . These constructs contain regions of the CD1 l b promoter extending either 1.5, 0.3, or 0.1 kb 5' from the transcription start site. In all constructs the CD1 l b promoter drives a reporter gene consisting of a human CD4 cDNA that has been mutated to prevent intracellular signaling, as described in the Materials and Methods. The hGH minigene is located at the 3' end of the transgene to improve transgene RNA stability and potentially enhance transgene gene showed the highest activity of a number of deletion constructs in transient transfection assays (Back, unpublished data). The 0. I-kb CD1 1 b promoter construct was made to test a published finding that 93 bp was sufficient for myeloid-specific promoter activity in transient transfection assays."
These three CD1 1 b promoter constructs were used to generate transgenic mice by microinjection of the male pronucleus of fertilized mouse eggs. Transgene-positive animals were identified by slot blot hybridization of DNA extracted from the tails of offspring with a 1.7-kb human CD4 cDNA probe. Eleven founder lines were successfully bred to establish heterozygous lines: three lines of CD1 Ib 1.5-kb promoter-hCD4-hGH mice; four lines of CDllb 0.3-kb promoter-hCD4-hGH mice; and four lines of CD1 l b 0. I-kb promoter-hCD4-hGH mice. Three other founder mice were positive on the initial slot blot analysis but did not pass the transgene to offspring and are presumed to be mosaics. Three additional transgene-positive founder animals ( 1 S-kb CD1 1 b-hCD4-hGH) were sterile.
Transgene integrity and copy number. To evaluate transgene integrity and estimate copy number, Southern blots were performed (Fig 2) . For the I S-kb CD1 Ib promoterhCD4-hGH founders, DNA was digested with Bgl I1 and the resulting blot was hybridized with the 1.7-kb human CD4 probe, which should identify a 4.4-kb restriction fragment. For the 0.3-kb and 0. l-kb CD1 1 b promoter-hCD4-hGH founders, tail DNA was digested with BamHI and the resulting blot was hybridized with the 1.7-kb human CD4 probe, which should identify a 1.7-kb restriction fragment. These blots verify that the transgenes were integrated into the mouse germline without rearrangement. In all founder lines that were bred, transgenes were integrated intact (Fig   2) . This excludes the possibility that lack of transgene expression is caused by disruption of the transgene during or after integration into germline DNA. One of the founders (F49) demonstrated transgene rearrangement and was not analyzed further. Relative transgene copy numbers were estimated to range from 1 to 10 (Fig 2 and Table l ) .
Expression of CD1 I b promoter-hCD4-hCH transgene RNA. RNA slot blots were made and probed with the 1.7-kb human CD4 reporter transgene to assess RNA expression in different organs of transgenic mice from different founder lines. If the CD1 I b promoter were sufficient to direct the tissue-specific expression of CD1 Ib, the CD1 Ib promoterhCD4-hGH transgenes would be expressed predominantly in myeloid cells and would be detected easily in bone marrowderived RNA on slot blots or Northern blots. This tissuespecific pattern of CD1 I b expression has been demonstrated in human^^,^.*^ and in mice.*' Slot blots from three founder lines of the 1 S-kb CD1 1 b promoter-hCD4-hGH transgenic mice are shown in Fig 3. In the nontransgenic control mouse (column l), no human CD4 reporter transgene RNA is detected in any organ. SupTl denotes RNA isolated from a human lymphocyte cell line that expresses human CD4 and was used as a positive control. Of the three 1.5-kb CD1 Ib promoter-hCD4-hGH founder lines, one founder line (F84) expresses transgene RNA easily detected after an overnight exposure in the spleen, thymus, and bone marrow. Another founder line (F88) expresses similar levels of transgene RNA in spleen and lymph node, and lower levels in bone marrow and liver. The transgenic mice were performed to verify the hematopoietic lineage of cells expressing the human CD4 reporter transgene. Peripheral blood leukocytes were stained simultaneously with pairs of anti-hCD4 and cell lineage markers for B lymphocytes, (murine B220), monocytes, and granulocytes (murine CD1 Ib and murine . If the CD1 Ib promoter were sufficient to direct the tissue-specific expression of CD I 1 b. the CD 1 l b promoter-hCD4-hGH transgenes would be expressed predominantly in myeloid cells and the hCD4 reporter gene product would be detectable by flow cytometry on peripheral blood granulocytes as well as a small percentage of B lymphocytes.
Our CD1 1 b promoter transgenic lines did not consistently demonstrate the expected pattern of hCD4 expression on peripheral blood leukocytes ( Table l) . The 1 S-kb CD1 1 b promoter founder lines demonstrating the highest levels of transgene RNA expression had the highest levels of surface expression of the human CD4 reporter transgene on peripheral blood leukocytes (Fig 4) . One 1 S-kb founder line (F84) expresses human CD4 primarily in granulocytes (Fig 4, row  2) . One 1.5-kb founder line (F88) expresses human CD4 in granulocytes and lymphocytes (Fig 4, row 3 ine the expression of the human CD4 reporter transgene in lymphocyte subsets (Fig 5) .
If the CD1 Ib promoter was sufficient to direct the tissue-specific expression of C D l l b , the hCD4 reporter gene product would be detectable by flow cytometry only on a small percentage of CD5+ B lymphocytes.hx
The only two founder lines with transgene expression in lymphoid cells (F88 = 1.5 kb, F3 = 0.1 kb) show that the hCD4 transgene is expressed, inappropriately, in many CD5-splenocytes (Fig 5 , column 4) . In founder F88 (1.5 kb), a small population of CD5' splenocytes expresses the transgene (Fig 5 , column 4, row 2 ), but most of the splenocytes that express hCD4 are CD5
. In founders F88 and F3, small populations of CD1 lb', hCD4' splenocytes are present (Fig 5 , column S) , but the majority of splenocytes that express hCD4 are CD1 1 h". The transgene expression observed in splenocytes is not parallel to expression of the endogenous murine CD I 1 b gene.
Trunsgene expression on peritoneul macrophuges directed by the C D l l b promoter. A two-color cytofluorometric analysis of peritoneal macrophages was performed to evaluate expression of the human CD4 reporter gene in myeloid cells outside of peripheral blood (Fig 6) . Peritoneal macrophages were used to examine transgene expression in myeloid cells other than granulocytes. If the CD1 1 b promoter were sufficient to direct tissue-specific regulation of 
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CD1 Ib, the hCD4 reporter gene product should be detectable on peritoneal macrophages from the CD1 Ib promoter transgenic mice.
Peritoneal macrophages were stained simultaneously with pairs of anti-hCD4 and either murine CD1 Ib or murine Gr-1. The founder lines that express the hCD4 transgene in peripheral blood granulocytes also express the hCD4 transgene in peritoneal macrophages. Data from 1.5-kb founder lines are shown (F88) demonstrating appropriate expression of the hCD4 transgene in peritoneal macrophages.
DISCUSSION
This study indicates that the CD1 Ib proximal promoter directs expression of a human CD4 reporter gene in the leukocytes of transgenic mice, although transgene expression appears to be dependent on integration site and is not related to transgene copy number. Three of eleven founder lines demonstrated easily detectable levels of transgene-derived human CD4 on the surface of peripheral blood leukocytes. In these three founder lines, transgene expression was documented in granulocytes and peritoneal macrophages, as would be expected from the normal pattern of CD1 1 b expression, but, in addition, transgene expression in two founder lines was documented in lymphocytes in a pattern not characteristic of normal CD1 Ib expression. These results suggest that distant DNA regulatory sequences not included in the 1.5-kb CD1 Ib proximal promoter are required to direct gene expression in hematopoietic cells in a pattern paralleling the endogenous CD 1 1 b gene.
CD1 I b expression in human and murine hematopoietic cells is largely restricted to terminally differentiated myeloid cells. In the CD1 Ib promoter transgenic founder lines that expressed the human CD4 reporter gene, tissue specificity for myeloid cells was not observed. Two of the three founder lines (F88 = 1.5 kb, F3 = 0. I kb) with the highest levels of expression showed human CD4 surfdce expreasion on lymphocytes, as well as in granulocytes. Although transgene expression in CD5' B lymphocytes would be consistent with the tissue distribution of the endogenous CD 1 1 b gene, most of the CD5+ splenocytes did not express the human CD4 reporter transgene. The transgene expression observed in lymphocytes cannot be explained by an expanded CD4-or CD8' compartment, in which small subsets of CD1 Ib-cells are normally present. These results suggest that the complete set of regulatory sequences controlling lineage-specific expression of CD1 Ib in granulocytes or lymphocytes is not contained within the 1.5-kb proximal CD1 Ib promoter.
However, some of the sequences important for CD1 Ib expression may be present within the 1. studies initially identified nine transgene-positive 1.5-kb founders. Threc of these animals were sterile. Of the remaining six animals that were bred, two failed to produce any transgene-positive offspring, and one demonstrated a rearranged transgene on Southern blots. Thus, three lines of 1.5-kb mice were available for complete analysis. The three sterile 1.5-kb founder animals were analyzed for transgene expression in peripheral blood leukocytes; none showed any transgene expression. Taken together, these results suggest that, although the CD1 l b proximal promoter contains some of the sequences required for hematopoietic tissue specificity, it does not contain all of the sequences required for regulated expression of CD1 l b in myeloid cells.
Previous studies using transient transfections have shown that Spl and PU. 1 are important for the expression of CD I 1 b in myeloid cells'*~" and have suggested that the CD1 l b promoter is myeloid specific. However, transgenic animals represent a more stringent test of tissue specific expression than transfection of cell lines in vitro. The transgene expression mediated by the CD1 1 b promoter described in this report indicates that the 1.5-kb CD1 Ib promoter is not sufficient for high-level gene expression in myeloid cells. A transgenic construct using the entire C D l l b gene, including S', 3', exon, and intron sequences, would be extremely valuable in light of these results, because fully regulated expression of CD1 1 b may require a number of disparately located elements. Because the CD1 l b gene spans more than SO kb" this type of transgenic construct would require use of large genomic sequences, requiring Pls or yeast artificial chromosomes.
Two features of the transgene constructs could have an effect on the reporter gene expression mediated by the CD I 1 b promoter. First, the human CD4 reporter gene could have some unanticipated effect on transgene expression. Although the human CD4 cDNA used in these transgenes was mutated by truncating the cytoplasmic domain, to minimize the effect on the cells expressing the transgene, it might be possible for the transgene to be toxic to the cells expressing the transgene. However, among the founder lines, transgene RNA expression paralleled surface expression of the human CD4 reporter. There was no instance in which an animal showing high levels of transgene expression in bone marrow showed no hCD4 surface expression on peripheral leukocytes. In addition, surface expression of human CD4 was seen in the tissues expressing the highest levels of hCD4 RNA. Thus, an hCD4 effect on transgene expression seems unlikely, which indicates that the hCD4 reporter gene may be useful in other transgenic studies involving murine hematopoietic cells. Second, the hGH minigene located at the 3' end of the transgenic constructs could have affected transgene expression. Previous studies show that including hGH in the transgene is likely to enhance expression, because the hGH minigene causes the transgene transcript to be spliced, which increases its stability." This effect seems most likely to enhance the levels of transgene expression in tissues in which the CD1 l b promoter drives some (perhaps minimal) level of transgene expression. Thus, the presence of the hGH minigene in the transgenic construct would be predicted to increase, rather than decrease, transgene expression.
Transgenic studies have been extremely valuable in characterizing the regulated expression of other tissue-specific genes. Gene expression in lymphoid cells has been demonstrated successfully in transgenic mice, and these studies have been useful in identifying lymphoid-specific sequences. Transgenic mice made with the human CGL-Ugranzyme B promoter, for instance, demonstrated expression to activated T lymphocyte^.^^ Transgenic studies of other tissue-specific genes have shown more complex regulatory mechanisms.
Initial transgenic studies using the p globin promoter showed very low-level transgene expression, as well as ectopic tissue transgene e x p r e s s i~n .~~ Further work led to the incorporation of distant hypersensitive site sequences (now termed the locus control region) into the transgenic constructs, resulting in high-level, erythroid-specific transgene expression and even recapitulation of the tissue-specific and developmental stage-specific sequence of globin expression." As in the globin paradigm, distant sequences may be critical for the tissue-specific and developmental stage-specific regulation of CD1 Ib in myeloid cells.
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The molecular mechanisms that control human myeloid tissue specificity in gene expression have not been well defined using in vivo experimental systems. Studies of genes expressed in myeloid cells have not identified discrete sequences responsible for myeloid tissue specificity in transgenic mice. The human c-fps/fes gene encodes a tyrosine kinase expressed in immature and mature myeloid cells and, when a 13-kb genomic fragment was used to make transgenic mice, RNA expression was demonstrated in bone marrow, bone marrow-derived macrophages, and spleen, although not directly in granulocytes. 26 The human gp-9lphox promoter, normally driving the gp9lphox gene expressed in granulocytes, has also been used in transgenic mice, but unexpectedly yielded reporter gene expression only in monocytes and macrophages-not in granul~ytes.~' Myeloidspecific genes in nonhuman species have also been studied. Tissue-specific expression in chicken macrophages has been extensively studied using the chicken lysozyme gene.28s29 These studies indicate that enhancer sequences located as far as 6.1 kb from the coding sequence are important for myeloid-specific expression of chicken lysozyme. Mouse M W 8 and MW14 are calcium-binding proteins expressed in myeloid cells. The M W 8 promoter has been used to express bcl-2 in granulocytes of transgenic mice, but tissue specificity directed by this promoter was not well described.30 The evidence to date suggests that selective gene expression in myeloid cells is controlled by disparately located regulatory sequences.
Regulatory sequences that direct myeloid gene expression might be useful to express biologically important molecules selectively in myeloid cells of transgenic mice or to target genes to myeloid cells for retroviral gene the rap^.^' Further study of the regulatory sequences controlling the expression of leukocyte integrin CDllb should provide insight into the molecular mechanisms of myeloid gene expression.
